Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 87 (pp. 1275-1295)    |    2023       

»

Liposomal system as an advanced route of inhaled drug administration (Literature review)

Gusak T.I., Ustinova T.M., Vengerovich N.G.

FSBI "State Research and Testing Institute of Military Medicine" of the Ministry of Defense of the Russian Federation

Brief summary

Inhalation therapy, unlike the oral and intravenous routes of administration, delivers the drug directly into the airway lumen. Direct lung delivery improves the drug safety, reduces its total therapeutic dose, and minimizes its impact on other body systems. In most cases, inhalation delivery allows a faster response to the drug administration and a prolonged duration of its action. Aerosol drug administration is a common therapeutic approach to respiratory diseases. Successful therapy requires delivery systems designed to penetrate into the lower respiratory tract and to be deposited there. There was considered an advanced drug delivery system - liposomes - in this review. Inhaled administration of liposomes should protect them from destruction by digestive lipases, from binding to serum proteins (opsonins) and their elimination from blood, as well as from their absorption by hepatic and splenic macrophages. The purpose of this review was to confirm the liposomal formulations? suitability for inhaled drug delivery directly to the lung nidi (niduses). The review describes the main characteristics determining the distribution and behavior of liposomes in the lungs. The mass median aerodynamic diameter data are given for liposomes to reach the lower respiratory tract. The composition of liposomes, which allows increasing their lung penetration, is considered. The correlation between the main phase transition temperature and the lipid membrane permeability is described. The patent and scientific publication data over the past 5 years in the field of liposomal system research for inhalation are presented to prove their effectiveness and safety as a targeted delivery system. According to the literature review results, optimal composition variants and liposome characteristics promising for inhaled administration were substantiated.


Key words

inhaled administration; liposomes; bilayer; surfactant; phospholipids; dipalmitoylphosphatidylcholine

Reference list

1. Shafei A., El-Bakly W., Sobhy A., Wagdy O. et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017; 95: 1209-1218. https:/doi.org/10.116/j.biopha.2017.09.059.


2. O?Brien M. E. R., Wigler N., Inbar M., Rosso R. et al. Reduced cardiotoxicity and compatable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15 (3): 440-449. https:/doi.org/10.1093/annonc/mdh097.


3. Jarvis J., Lawrence D., Meya D., Kagimu E. et al. Single-dose liposomal Amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 2022; 386 (12): 1109-1120. https:/doi.org/10.1056/NEJMoa2111904.


4. Groll H. A., Rijnders B. J. A., Walsh T. J., Adler-Moore J. et al. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal Amphotericin B. Clin Infect Dis.; 2019: 68 (4): 260-274. https:/doi.org/10.1093/cid/ciz076.


5. Fadeeva A. V. Otdalennie rezyltati lecheniya sybretinalnoi neovaskylyarizacii pri vozrastnoi makylodistrofii s ispolzovaniem preparata Vizydin y pacientov s pervichnoi otkritoygolnoi glaykomoi. Aspirantskii vestnik Povoljya Medicina. 2015; 1-2: 104-106.


6. Hlebnikova A. N., Molochkov A. V. Vozmojnosti liposomalnoi kosmetiki v terapii psoriaza. Rossiiskii jyrnal kojnih i venericheskih boleznei. 2015; 2: 31-34.


7. Strok A. B., Galeeva J. A. Osnovnie aspekti ispolzovaniya ingalyacionnih sredstv dostavki lekarstvennih preparatov v lechenii zabolevanii dihatelnih pytei. Klinicheskaya farmakologiya. 2011; 2: 10-15.


8. Morozov V. N., Kanev I. L. Ystroistvo kontrolya zaryada biologicheski aktivnih nanoaerozolei: pat.2656762 Ros. Federaciya: MPK A61M 15/60, B82Y 5/00; 2017130197.


9. Ignatova G. L., Belevskii A. S. Sovremennie sposobi ingalyacionnoi dostavki lekarstv pri lechenii bronhoobstryktivnih zabolevanii. Astma i allergiya. 2018; 2: 21-28.


10. Abashkin D. Nanochastici - instryment adresnoi dostavki lekarstv. Available at: https:/biomolecula.ru/articles/nanochastitsy-instrument-adresnoi-dostavki-lekarstv


11. Nkadi P. O., Merritt T. A., Pillers D. A. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. Mol Genet Metab.; 2009: 97 (2): 95-101. https:/doi.org/10.1016/j.ymgme.2009.01.015.


12. Tolkach P. G., Basharin V. A., Chepyr S. V., Nikiforov A. S. i dr. Issledovanie vliyaniya perftorizobytilena na lipidnii sostav syrfaktanta in vitro. Yspehi sovremennoi biologii. 2019; 139 (5): 500-505.


13. Kotta S., Aldawsari H. M., Bard-Eldin S. M., Binmahfouz L. S. et al. Aerosol delivery of surfactant liposomes for management of pulmonary fibrosis: An approach supporting pulmonary mechanics. Pharmaceutics; 2021: 13 (11): 1851. https:/doi.org/10.3390/pharmaceutics13111851.


14. Rozenberg O. A. Preparati legochnogo syrfaktanta i syrfaktant-terapiya ORDS v ysloviyah hiryrgicheskoi reanimacii (obzor literatyri). Kreativnaya hiryrgiya i onkologiya. 2019; 9 (1): 50-65.


15. Arber Raviv S, Alyan M., Egorov E., Zano A. et al. Lung targeted liposomes for treating ARDS. J Control Release; 2022: 346: 421-433. https:/doi.org/10.1016/j.conrel.2022.03.028.


16. Kotovich I. L., Taganovich A. D. Diagnosticheskoe znachenie issledovaniya kletok, citokinov i komponentov syrfaktanta legkih v bronhoalveolyarnoi lavajnoi jidkosti. Medicinskie novosti. 2000; 9: 5-8.


17. Svistelnik A. V., Hanin A. L. Liposomalnie lekarstvennie preparati: vozmojnosti i perspektivi. Medicina. 2014; 3 (2): 7-16.


18. Adel I. M., ElMeligy M. F., Abdelrahim M. E. A., Maged A. et al. Design and Characterization of spray-dried proliposomes for the pulmonary delivery of curcumin. Int J Nanomedicine; 2021: 16: 2667-2687. https:/doi.org/10.2147/IJN.S306831.


19. Kotovich I. L., Rytkovskaya J. A., Taganovich A. D. Pokazateli okislitelnogo stressa v legkih pri ingalyacionnom vvedenii liposom na osnove yaichnogo lecitina v ysloviyah eksperimentalnoi giperoksii. Biomedicina. 2019; 19 (3): 49-58.


20. Shvecov I. S., Poroiskii S. V., Stryssovskaya O. G. Sovershenstvovanie tehnologii i perspektivi primeneniya liposom (tematicheskii obzor). Volgogradskii naychno-medicinskii jyrnal. 2020; 4: 3-8.


21. Selisheva A. A., Tihonov V. P. Liposomalnaya kompoziciya antioksidantov dlya ingalyacii pri zabolevaniyah legkih i verhnih dihatelnih pytei: pat. 2315593 Ros. Federaciya: MPK A61K 9/107, A61K 9/127, A61K 9/72, A61K 36/00, A61K 31/375, A61K 31/352, A61R 11/00; 2006128005/15.


22. Byshmakina I. M., Martinova M. A., Knyazeva E. V. XXI vek: kak izmenilis nashi predstavleniya o liposomalnih lekarstvennih sredstvah. Himiko-farmacevticheskii jyrnal. 2015; 49 (2): 41-49.


23. Sanjakov M. A., Ipatova O. M., Torhovskaya T. I. Nanochastici kak sistemi transporta dlya protivotyberkyleznih sredstv. Vestnik RAMN. 2013; 8: 37-44.


24. Filatova L. U., Klyachko N. L., Kydryashova E. V. Adresnaya dostavka protivotyberkyleznih preparatov v makrofagi: nacelivanie na mannoznie receptori. Yspehi himii. 2018; 87 (4): 374-391.


25. Akbarzadeh A., Rezaei-Sadabady R., Davaran S., Woo Joo S. et al., Liposome: classification, preparation, and application. Nanoscale Res Lett; 2013: 8 (102): 1-9. https:/doi.org/10.1186/1556-276X-8-102.


26. Barishnikova M. A., Zangieva M. T., Barishnikov A. U. Vzaimodeistvie lipidnih nanokapsyl s kletkoi. Rossiiskii bioterapevticheskii jyrnal. 2012; 12 (1): 11-15.


27. Alekseeva A. S. Mehanizmi vzaimodeistviya s kletkami protivoopyholevih liposom s lipofilnimi prolekarstvami: dis. kand. him. nayk: M., 2018.


28. Alyaytdin R. N., Iejica I. N., Agarval R. Transport lekarstvennih sredstv cherez rogovicy glaza: perspektivi primeneniya liposomalnih lekarstvennih form. Vestnik oftalmologii. 2014; 4: 117-122.


29. El-Hammadi M. M., Arias J. L., An update on liposomes in drug delivery: a patent review (2014-2018). Expert Opin Ther Pat.; 2019: 41: 449-470. https:/doi.org/10.1080/13543776.2019.1679767.


30. Maestrelli F., Gonzalez-Rodrigues M. L., Rabasco A. M., Mura P. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int J Pharm; 2006: 317 (1-2): 53-60. https:/doi.org/10.1016/j.ijpharm.2005.12.047.


31. Kyzyakova L. M. Konstryirovanie transdermalnih liposomalnih preparatov s zadannimi svoistvami. Vestnik Moskovskogo yniversiteta Seriya 2. Himiya. 2005; 46 (1): 74-79.


32. Novikova A. A., Kezimana P., Stanishevskii Ya. M. Metodi polycheniya liposom, ispolzyemih v kachestve nositelei lekarstvennih sredstv (obzor). Razrabotka i registraciya lekarstvennih sredstv. 2017; 2: 134-138.


33. Gorbik V. S., Shprah Z. S., Kozlova J. M. Liposomi kak sistema targetnoi dostavki lekarstvennih sredstv (obzor). Rossiiskii bioterapevticheskii jyrnal. 2021; 20 (1): 33-41.


34. Nait Dj. V., Gilbert B., Voldrep Dj. K., Koshkina N. i dr. Liposomnie aerozoli s malim razmerom chastic dlya dostavki protivorakovih lekarstvennih preparatov: pat. 2223749 Ros. Federaciya: MPK A61K 9/12, A61K 9/127, A61R 35/00; 2000110113/14.


35. Rudokas M., Najlah M., Alhnan M. A., Alhissi A. Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications. Med Princ Pract; 2016: 25 (2): 60-72. https:/doi.org/10.1159/000445116.


36. Lisovaya E. V., Lisovoi V. V., Viktorova E. P., Marchenko L. A. Primenenie liposomalnih sistem, polychennih iz rastitelnih lecitinov, v pishevih tehnologiyah. Novie tehnologii/New technologies. 2019; 3: 51-60.


37. Shanskaya A. I., Pychkova S. M. Liposomalnie nanosistemi na osnove soevih fosfolipidov kak konteiner dlya lekarstvennih sredstv. Transfyziologiya. 2013; 14 (2): 66-75.


38. Chono S., Tagami K., Itagaki S. Aerosolized liposomes with dimalmithoyl phosphatidylcholine enhance pulmonary absorption of encapsulated insulin compared with co-administrated insulin. Drug Dev Ind Pharm.; 2017: 43 (11): 1892-1898. https:/doi.org/10.1080/03639045.2017.1353521.


39. Chen W., Dusa F., Witos J., Ruokonen S. K. et al. Determination of the main phase transition temperature of phospholipids by nanoplasmonic sensing. Sci Rep.; 2018: 8 (1): 1-11. https:/doi.org/10.1038/s41598-018-33107-5.


40. Kabral-Lilli D., Maier L., Tardi P., Yotkins D. i dr. Liofilizirovannie liposomi: pat. 2780489 Ros.Federaciya: MPK A61K 9/127, A61K 31/4745, A61K 31/704, A61K 31/7068, A61R 35/00, A61R 31/00, A61R 9/00; 2018107407.


41. Tai T. T., Wu T. J., Wu H. D., Tsai Y. C. et al. A strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine: a preclinical pharmacokinetic study. Clin Transl Sci.; 2021: 14 (1): 132-136. https:/doi.org/10.1111/cts.12923.


42. Dmitrieva M. V., Timofeeva T. A., Oborotova N. A. Harakteristika i ocenka stabilnosti liposomalnih preparatov. Razrabotka i registraciya lekarstvennih sredstv. 2018; 3: 36-44.